Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration

对以下评论的回应：一项前瞻性、随机、平行组、双盲、多中心研究，旨在比较 Lupin 公司的雷珠单抗与 Lucentis 在新生血管性年龄相关性黄斑变性患者中的疗效、安全性和免疫原性。